Phase 2 BANDIT trial demonstrates Eli Lilly's Olumiant (baricitinib) can slow progression of type 1 diabetes by preserving insulin-producing beta cell function over 48 weeks of treatment.
Ainos has secured TFDA approval for a clinical trial of VELDONA in HIV-related oral warts and IRB clearance for a Sjögren's Syndrome study, targeting two rare diseases with significant unmet needs.
Ainos is set to begin a Phase 3 clinical trial in Taiwan in December 2024 to assess Veldona, a low-dose interferon-alpha formulation, for primary Sjögren's disease.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.